Skip to main content

Advertisement

SpringerLink
Log in

Stones

Tolvaptan might prevent kidney stone formation

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Tolvaptan, an arginine vasopressin receptor antagonist, decreases urinary supersaturation in kidney stone formers by considerably increasing diuresis, suggesting that this drug might be an effective therapy for reducing the risk of developing kidney stones in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cheungpasitporn, W., Erickson, S. B., Rule, A. D., Enders, F. & Lieske, J. C. Short term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate, and uric acid supersaturations. J. Urol. http://dx.doi.org/10.1016/j.juro.2015.11.027 (2015).

  2. Borghi, L. et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J. Urol. 3, 839–843 (1996).

    Google Scholar 

  3. de Boer, H., Roelofsen, A. & Janssens, P. M. Antidiuretic hormone antagonist to reduce cystine stone formation. Ann. Intern. Med. 6, 459–460 (2012).

    Article  Google Scholar 

  4. Watkins, P. B. et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 11, 1103–1113 (2015).

    Article  Google Scholar 

  5. Hanouna, G., Haymann, J. P., Baud, L. & Letavernier, E. Vasopressin regulates renal calcium excretion in humans. Physiol. Rep. 3, e12562 (2015).

    Article  Google Scholar 

  6. Decaux, G., Van Laethem, Y., Van Kuyck, M. & Mockel, J. Hypercalciuria in the syndrome of inappropriate secretion of antidiuretic hormone. Miner. Electrolyte Metab. 4, 192–196 (1982).

    Google Scholar 

  7. Chang, Y. L., Lin, A. T. & Chen, K. K. Short-term effects of desmopressin on water and electrolyte excretion in adults with nocturnal polyuria. J. Urol. 6, 2227–2229 (2007).

    Article  Google Scholar 

  8. Tamma, R. et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc. Natl Acad. Sci. USA 46, 18644–18649 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emmanuel Letavernier and Michel Daudon are at the Sorbonne Universités, UPMC Univ Paris 06, UMR S 702, F-75020, Paris, France; INSERM, UMR S 1155, F-75020, Paris, France; and the Physiology Unit, AP-HP, Hôpital Tenon, F-75020, Paris, France.,

    Emmanuel Letavernier & Michel Daudon

  2. INSERM, UMR S 1155, F-75020, Paris, France,

    Emmanuel Letavernier & Michel Daudon

Authors
  1. Emmanuel Letavernier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Daudon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Emmanuel Letavernier or Michel Daudon.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Letavernier, E., Daudon, M. Tolvaptan might prevent kidney stone formation. Nat Rev Urol 13, 130–131 (2016). https://doi.org/10.1038/nrurol.2016.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.11

  • Springer Nature Limited

This article is cited by

Search

Navigation